abstract
- The clinical value of biocompatible peritoneal dialysis solutions is uncertain because of inconsistent findings in randomized controlled trials. A systematic review by Cho et al. examining 20 such trials suggests a beneficial effect on residual renal function. However, the finding is not robust and may relate to decreased ultrafiltration causing hypervolemia. Future prescribing of these biocompatible solutions will probably continue to be driven by opinion, marketing, and cost considerations rather than by evidence-based medicine.